MAP
PTGX icon

Madison Avenue Partners’s Protagonist Therapeutics PTGX Stock Holding History

Madison Avenue Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-406,593
Closed -$4.44M – 23
2022
Q4 		$4.44M Buy
+406,593
New +$3.43M 0.79% 17

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Madison Avenue Partners's PTGX Position: Q1 2023 in Review

Madison Avenue Partners sold out of Protagonist Therapeutics (PTGX) in Q1 2023, closing a stake of 406,593 shares — an estimated $4.44M sold.

Madison Avenue Partners first reported a position in PTGX in Q4 2022 and held it in 1 quarter. The position peaked at $4.44M in Q4 2022. 137 funds tracked by Wall St. Rank hold PTGX as of Q1 2023.

  • Madison Avenue Partners reported no remaining Protagonist Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Madison Avenue Partners sold 406,593 Protagonist Therapeutics shares in Q1 2023, an estimated $4.44M.
  • Madison Avenue Partners first reported a position in Protagonist Therapeutics in Q4 2022 and held it in 1 quarter.
  • Madison Avenue Partners's Protagonist Therapeutics position peaked at $4.44M in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2023.

Based on Madison Avenue Partners's 13F filing for Q1 2023, filed 15 May 2023.